Extracted from this filing and checked against the source text.
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
ANGIODYNAMICS INC completed a disposition involving Merit Medical Systems, Inc. for $100,000,000 in cash (closed 2023-06-08).
- Action
- disposition
- Counterparty
- Merit Medical Systems, Inc.
- Consideration
- $100,000,000 in cash
- Closing
- 2023-06-08
Exact text from the filing
to which Merit acquired the dialysis product portfolio and BioSentry tract sealant system biopsy product of AngioDynamics (the “ Business ”) for a purchase price equal to $100,000,000 in cash, subject to the terms and conditions of the Asset Purchase Agreement (the “ Transaction ”). The Transaction was effective as of 12:01 a.m. mountain time on June 8, 2023
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ANGIODYNAMICS INC entered into Asset Purchase Agreement with Merit Medical Systems, Inc. valued at $100,000,000 (effective 2023-06-08).
- Action
- entry
- Agreement
- asset purchase
- Counterparty
- Merit Medical Systems, Inc.
- Value
- $100,000,000
- Effective
- 2023-06-08
Exact text from the filing
On June 8, 2023, AngioDynamics, Inc., a Delaware corporation (“ AngioDynamics ” or the " Company "), entered into an asset purchase agreement (the “ Asset Purchase Agreement ”) with Merit Medical Systems, Inc., a Utah corporation (“ Merit ”), pursuant to which Merit acquired the dialysis product portfolio and BioSentry tract sealant system biopsy product of AngioDynamics (the “ Business ”) for a purchase price equal to $100,000,000 in cash, subject to the terms and conditions of the Asset Purchase Agreement (the “ Transaction ”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ANGIODYNAMICS INC terminated Credit Agreement with lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and KeyBank National Association, as co-syndication agents, and JPMorgan Chase Bank N.A., as sole bookrunner and sole lead arranger (effective 2022-06-08).
- Action
- termination
- Agreement
- credit facility
- Counterparty
- lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and KeyBank National Association, as co-syndication agents, and JPMorgan Chase Bank N.A., as sole bookrunner and sole lead arranger
- Effective
- 2022-06-08
Exact text from the filing
On June 8, 2022, AngioDynamics used a portion of the consideration received in connection with the Transaction to repay all amounts owed under AngioDynamics’ existing Credit Agreement, dated as of August 30, 2022, with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and KeyBank National Association, as co-syndication agents, and JPMorgan Chase Bank N.A., as sole bookrunner and sole lead arranger (the “ Credit Agreement ”), and as a result, the Credit Agreement was terminated.
View on SEC.gov